RedDress has begun shipments of their ActiGraft systems this week to multiple hospitals in Ukraine to help treat civilian casualties as a result of Russian attacks. An initial shipment of 400 units of the blood clotting wound care system is en route. 

RedDress says  this is the first time their technology will be deployed and used in a war zone.

RedDress is also coordinating with their partner medical specialists from GraftIn and SlavaMed to help with delivery into Ukraine, while another partner, Dr. Arkadiy Savchenko, a leading expert and Department Surgery No. 2 of Danylo Halytsky Lviv National Medical University, will lead the charge to teach Ukrainian nurses, doctors and aid workers, on how to use the systems. 

“We’re grateful we’re in a position to not only have a cutting-edge product that has a far greater success rate than traditional wound care treatment options, but also that we have the ability to be financially capable to donate these resources to help so many people in need,” says Robert Mueller, general manager of RedDress. 

ActiGraft is a proprietary and patented technology solution used to help with wound care that enables health care providers to produce—in real time—in vitro blood clots from a patient’s whole blood. Once applied, the blood clot supports wound management and naturally occurring processes in the patient’s body.

While still considered new technology, ActiGraft is quickly becoming a preferred treatment option, especially by doctors who treat complex wounds like those often seen in amputations, post-surgical patients, diabetic patients, vascularly compromised patients, and patients suffering from chronic and traumatic wounds. Showcasing the broad use, just last year, RedDress’s ActiGraft was recognized as one of the year’s Top 10 Innovations by Podiatry Today, a medical trade journal.